JAMA Cardiology

SEPTEMBER 3, 2024

This substudy of the SEQUOIA-HCM (Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy) randomized clinical trial investigates if treatment with aficamten improves exercise response beyond peak oxygen uptake measured by cardiopulmonary exercise testing (..)

Exercise 77

Exercise Cardiomyopathy 77

DAIC

JULY 10, 2024

Findings from an observational analysis of ARISE-HF trial participants, newly-published in the Journal of the American College of Cardiology, JACC, shed light on the racial and ethnic disparities in diabetic cardiomyopathy (DbCM), which researchers note may have the potential to inform clinical practice, interventions, and policies.

Cardiomyopathy 113

Cardiomyopathy Diabetes Health Disparities Exercise 113

HeartRhythm

DECEMBER 28, 2024

Desmoplakin (DSP) variants are associated with left-predominant or biventricular arrhythmogenic cardiomyopathy. Exercise promotes penetrance and sustained ventricular arrhythmias (VA) in right-sided arrhythmogenic right ventricular cardiomyopathy, but its effect is unknown in DSP variant carriers.

Exercise 81

Exercise Cardiomyopathy Arrhythmia 81

Physiologically Speaking

FEBRUARY 28, 2024

These numbers indicate rising participation — an increase in people involved in chronic endurance exercise training for the sake of competition and health. We know exercise, and especially a marathon, stresses the heart. ” Isn’t exercise good for us? ” Isn’t exercise good for us? 

Exercise 98

Exercise Sudden Cardiac Death Physiology Congenital 98

American College of Cardiology

APRIL 8, 2024

Treatment with AT-001, a highly selective aldose reductase inhibitor, had no significant effect on exercise capacity as measured by peak oxygen uptake (VO2) among individuals with diabetic cardiomyopathy (DbCM), according to results from a Late-Breaking Clinical Trial.

Exercise 53

Exercise Cardiomyopathy Diabetes Article 53

American Heart News - Heart News

MAY 8, 2024

WASHINGTON and DALLAS (May 8, 2024) – The American College of Cardiology (ACC) and the American Heart Association (AHA) today released a new clinical guideline for effectively managing individuals diagnosed with hypertrophic cardiomyopathy (HCM).

Cardiomyopathy 62

Cardiomyopathy Exercise 62

Circulation

NOVEMBER 8, 2024

BACKGROUND:Patients with hypertrophic cardiomyopathy without left ventricular outflow tract obstruction commonly experience reduced exercise capacity. Physical training improves exercise capacity in these patients, but whether the underlying effects of exercise are a result of central hemodynamic or peripheral improvement is unclear.

Exercise 49

Exercise Cardiomyopathy Quality of Life Pulmonary 49

Heart BMJ

APRIL 25, 2024

Clinical introduction A patient in his 60s with a history of ischaemic cardiomyopathy and severely reduced left ventricular ejection fraction of 20% presents with worsening dyspnoea on exertion. mL/kg/min) despite maximal effort. The test was stopped due to shortness of breath. Plots 1 and 2 from the CPET are shown in figure 1A and B.

Exercise 52

Exercise Cardiomyopathy Defibrillator 52

NEJM Journal Watch - Cardiology

MAY 11, 2024

New recommendations include exercise prescription and treatment with cardiac myosin inhibitors.

Cardiomyopathy 80

Cardiomyopathy Exercise 80

Frontiers in Cardiovascular Medicine

JANUARY 3, 2024

Hypertrophic cardiomyopathy is the most common genetic cardiac disorder and is defined by the presence of left ventricular (LV) hypertrophy in the absence of a condition capable of producing such a magnitude of hypertrophy. Over the past decade, guidelines on the screening, diagnostic, and management protocols of pediatric primary (i.e.,

Pediatrics 87

Pediatrics Cardiomyopathy Heart Failure Exercise 87

American College of Cardiology

NOVEMBER 15, 2024

What is the effect of exercise training on left ventricular (LV) filling pressure measured during exercise in patients with hypertrophic cardiomyopathy (HCM) without left ventricular outflow tract (LVOT) obstruction?

Exercise 53

Exercise Cardiomyopathy Article 53

DAIC

MARCH 25, 2025

Efficacy of finerenone according to left atrial size in patients with heart failure and mildly reduced or preserved ejection fraction: An analysis of the FINEARTS-HF trial during the session " Finerenone: A Promising Addition to the Armamentarium or Merely an Academic Exercise?"

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Kidney Disease Research 52

Nature Reviews - Cardiology

MAY 27, 2024

Nature Reviews Cardiology, Published online: 28 May 2024; doi:10.1038/s41569-024-01044-8 Data from the SEQUOIA-HCM trial show that aficamten, a cardiac myosin inhibitor, increases exercise capacity and improves quality of life in patients with symptomatic obstructive hypertrophic cardiomyopathy.

Cardiomyopathy 59

Cardiomyopathy Quality of Life Exercise 59

American College of Cardiology

NOVEMBER 20, 2024

In this week’s View, Dr. Eagle looks at exercise training in patients with hypertrophic cardiomyopathy (HCM).

Exercise 58

Exercise Cardiomyopathy Article 58

American College of Cardiology

JULY 2, 2024

What is the effect of AT-001, an aldose reductase inhibitor, on exercise capacity among individuals with diabetic cardiomyopathy (DbCM) with reduced exercise capacity and at high risk for progression to overt heart failure (HF)?

Cardiomyopathy 53

Cardiomyopathy Diabetes Exercise Heart Failure 53

NEJM Journal Watch - Cardiology

APRIL 30, 2024

The highly selective aldose reductase inhibitor AT-001 did not improve exercise capacity in a randomized trial.

Cardiomyopathy 81

Cardiomyopathy Diabetes Exercise Outcomes 81

HCPLive

MAY 9, 2024

Compass Pathways reports positive results for psilocybin in PTSD treatment, showing safety and symptom improvement in an open-label phase 2 study.

Exercise 72

Exercise Cardiomyopathy 72

Nature Reviews - Cardiology

APRIL 22, 2024

Nature Reviews Cardiology, Published online: 23 April 2024; doi:10.1038/s41569-024-01032-y According to data from the IMPROVE-HCM trial, ninerafaxstat is well tolerated by patients with symptomatic non-obstructive hypertrophic cardiomyopathy and improves exercise performance among those who are most symptomatically limited.

Cardiomyopathy 55

Cardiomyopathy Exercise 55

MIBHS

FEBRUARY 28, 2025

While much attention is given to modifiable risk factors such as diet, exercise, and smoking, the role of genetics in heart disease is equally critical yet less understood by the general public. Cardiomyopathies: These diseases affect the heart muscle, impairing its ability to pump blood effectively.

Genetic predisposition 52

Genetic predisposition Heart Disease Cholesterol Blood Pressure 52

HeartRhythm

OCTOBER 19, 2023

Hypertrophic cardiomyopathy (HCM)-related sudden cardiac death (SCD) rates with contemporary management are low; however, high-intensity exercise can induce fatal arrhythmias in HCM patients. Thus, current guidelines recommend avoiding high-intensity exercise in HCM patients at high risk for SCD1,2.

Exercise 40

Exercise Cardiomyopathy Sudden Cardiac Death Cardiovascular Disease 40

HeartRhythm

MARCH 25, 2025

Ventricular arrhythmias (VAs) may be the first clinical manifestation in pediatric patients with arrhythmogenic cardiomyopathy (ACM). The arrhythmogenicity of exercise testing (ET) remains unclear.

Pediatrics 40

Pediatrics Exercise Arrhythmia Cardiomyopathy 40

American College of Cardiology

MARCH 12, 2025

Although the 2024 ACC/American Heart Association (AHA) and 2023 European Society of Cardiology (ESC) guidelines stratify well overall the risk of sudden cardiac death (SCD) in patients with hypertrophic cardiomyopathy (HCM).

Sudden Cardiac Death 66

Sudden Cardiac Death Exercise Research Cardiomyopathy 66

HeartRhythm

APRIL 30, 2024

Introduction: Pathogenic desmoplakin (DSP) variants are associated with left or biventricular arrhythmogenic cardiomyopathy. Exercise promotes penetrance and sustained ventricular arrhythmias (VA) in classic ARVC. It is unknown if exercise affects risk in DSP variant carriers.

Exercise 40

Exercise Arrhythmia Cardiomyopathy 40

Journal of the American Heart Association

MARCH 7, 2025

BackgroundCardiac myosin inhibitors were recently developed to address the underlying pathophysiology of hypertrophic cardiomyopathy and to improve symptoms and quality of life. for Nterminal proBtype natriuretic peptide) while improving exercise parameters (improved placebocorrected peak oxygen consumption of at least 1.4

Cardiomyopathy 45

Cardiomyopathy Quality of Life Atrial Fibrillation Pharmacology 45

Circulation

JANUARY 12, 2025

Circulation, Volume 151, Issue 2 , Page 145-148, January 14, 2025.

Exercise 49

Exercise Cardiomyopathy Circulation 49

DAIC

APRIL 9, 2024

Maron, MD “Our findings provide enthusiasm that a novel drug therapy with ninerafaxstat may provide nonobstructive HCM patients an opportunity to achieve a better quality of life by decreasing symptom burden and improving exercise capacity,” said Martin S. For more information on hypertrophic cardiomyopathy, visit CardioSmart.org/HCM.

Cardiomyopathy 52

Cardiomyopathy Quality of Life Chest Pain Preserved Ejection Fraction 52

DAIC

MAY 9, 2024

The American College of Cardiology (ACC) and the American Heart Association (AHA) today released a new clinical guideline for effectively managing individuals diagnosed with hypertrophic cardiomyopathy (HCM). Ommen, MD, FACC , medical director of the Mayo Hypertrophic Cardiomyopathy Clinic and chair of the guideline writing committee.

Cardiomyopathy 52

Cardiomyopathy Pediatrics Quality of Life Sudden Cardiac Death 52

Open Heart

JUNE 9, 2022

Background This review aimed to compare the relative effectiveness of different exercise-based cardiac rehabilitation (ExCR) delivery modes (centre-based, home-based, hybrid and technology-enabled ExCR) on key heart failure (HF) outcomes: exercise capacity, health-related quality of life (HRQoL), HF-related hospitalisation and HF-related mortality.

Quality of Life 52

Quality of Life Cardiac Rehabilitation Exercise Heart Failure 52

Med Page Today

MAY 13, 2024

(MedPage Today) -- The novel cardiac myosin inhibitor aficamten improved peak oxygen uptake in symptomatic obstructive hypertrophic cardiomyopathy (HCM), the pivotal SEQUOIA-HCM trial showed. At 24 weeks, the mean change in the peak oxygen uptake.

Exercise 52

Exercise Cardiomyopathy 52

MIBHS

MARCH 15, 2025

Heavy and repeated binge drinking can lead to alcoholic cardiomyopathy, a condition in which the heart muscle weakens and struggles to pump blood efficiently. Other lifestyle factors, such as a healthy diet, regular exercise, and stress management, also play significant roles in maintaining heart health.

Blood Pressure 52

Blood Pressure Heart Rhythm Blood Clot Heart Disease 52

HeartRhythm

APRIL 30, 2024

Hypertrophic cardiomyopathy (HCM) is associated with a predisposition to lethal ventricular arrhythmias. LGE scar burden on MRI is thought to contribute to this risk, but its impact on electrophysiological substrate is not well understood.

Cardiomyopathy 40

Cardiomyopathy Electrophysiology Exercise Arrhythmia 40

HeartRhythm

APRIL 30, 2024

Autonomic remodeling is known to occur in premature ventricular contraction-induced cardiomyopathy (PVC-CM). However, the functional significance of this finding remains unclear.

Cardiomyopathy 40

Cardiomyopathy Exercise 40

Cardiovascular Ultrasound

NOVEMBER 3, 2024

Atrial cardiomyopathy is closely associated with atrial fibrillation (AF), and some patients exhibit no dysfunction at rest but demonstrate evident changes in left atrial (LA) function and LA volume during exe.

Atrial Fibrillation 52

Atrial Fibrillation Exercise Cardiomyopathy Research 52

European Journal of Heart Failure

SEPTEMBER 26, 2023

Exercise training in patients with advanced heart failure and left ventricular assist device (Ex-VAD) trial. 6MWT, 6-min walk test; KCCQ, Kansas City Cardiomyopathy Questionnaire physical domain score; peakVO 2 , peak oxygen consumption; RCT, randomized controlled trial. m (95% CI 16.9, p  = 0.0124), both after 12 weeks. m (95% CI 16.9,

Exercise 40

Exercise Heart Failure Quality of Life Cardiomyopathy 40

DAIC

MAY 6, 2024

Patients who transitioned to the oral daily formulation after a lengthy treatment with the weekly IV formulation improved further in this assessment of exercise tolerance, which is the primary endpoint of the ongoing Phase 3 LEVEL study. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,

Preserved Ejection Fraction 105

Preserved Ejection Fraction Heart Failure Pulmonary Hypertension 105

EMS 12-Lead

MAY 20, 2022

She reports a known history of Hypertrophic Cardiomyopathy (HCM) with left ventricular outflow tract obstruction and is on daily beta blocker therapy. Furthermore, she denies any hydration since conclusion of exercise. Diagnosis and management of hypertrophic cardiomyopathy: Expert analysis. References Naidu, S. Tower-Rader, A.

Cardiomyopathy 52

Cardiomyopathy Ischemia STEMI Coronary Angiogram 52

Circulation: Genomic and Precision Medicine

NOVEMBER 28, 2023

Background:Limiting high-intensity exercise is recommended for patients with arrhythmogenic right ventricular cardiomyopathy (ARVC) due to its association with penetrance, arrhythmias, and structural progression. Guidelines recommend shared decision-making (SDM) for exercise level, but there is little evidence regarding its impact.

Exercise 40

Exercise Cardiomyopathy Arrhythmia Circulation 40